Also in future, new therapeutic potentials such as anti-CRP, anti-TNF-α, anti-MCP-1, or anti-SAA agents could be considered as targets to reduce the risk of renal complications in T2DM. Here, CCL2 is linked to type 2 diabetes mellitus.